InterMune drug may offer big upside to Roche if aimed at liver
August 27, 2014 at 17:58 PM EDT
(Reuters) - Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.
